Wire · operational-macro
Compass Pathways CEO Kabir Nath on the promise of psychedelic medicine
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 October 2026 · Fusion42 review
Compass Pathways is advancing its synthetic psilocybin drug COMP360 for treatment-resistant depression, having secured a National Priority Voucher from the FDA which could accelerate approval. The company expects to submit its final application in Q4 2026 and aims for a US launch in early 2027, marking a potential new regulated medical pathway for psychedelic therapies.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 21 Oct 2026 and 2 Nov 2026.
◆ ◆ The Wire takeaway
Compass Pathways changing the medical treatment options for chronic depression means you must plan now for new clinical service models and reimbursement pathways. The window to connect with early adopter psychiatrists and payers is opening.
◆ Coverage
2 sources · first reported 21 Oct 2026 · latest 2 Nov 2026
◆ Related on Wire
◆ Topics